Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Michelle Johnson Named Chief Executive Officer of Metrum Research Group, Succeeding Founder Marc Gastonguay

Metrum Research Group

Metrum Research Group (MetrumRG), the global leader in biomedical modeling and simulation solutions, today named Michelle Johnson its Chief Executive Officer, succeeding founder Marc Gastonguay. Ms. Johnson was previously Chief Operating Officer of MetrumRG, where she provided strategic business direction for the fulfillment of MetrumRG’s mission and goals and was instrumental in building and leading a high-performance business team. Under the leadership of Ms. Johnson and the MetrumRG Executive Team, the company will maintain its founding principles, delivering the highest-quality solutions in quantitative sciences and technology, and growing the science as thought leaders in the community. “I am honored to lead this fantastic organization,” said Ms. Johnson. “Metrum Research Group sits at the intersection of the best scientific expertise and cutting-edge technology. We are excited for this next chapter in our growth and evolution, and I am particularly thankful to Marc and the entire Executive Team for their trust.” Dr. Gastonguay, who founded MetrumRG in 2004, will remain Chairman of the Board of Directors and will serve as a strategic advisor to Ms. Johnson and the Executive Team. “Given the growth and development of our world-class team and the opportunities in front of us, I knew it was time to hand over the reins and focus on governance vs. day-to-day management,” said Dr. Gastonguay. “Michelle was the undisputed choice for the CEO role. She is deeply valued internally by our team, and she has been a respected partner among our community and customers. All of our stakeholders are in the best hands with Michelle as our CEO.” Ms. Johnson joined MetrumRG in 2015, became a member of the Executive Team in 2017. She was named COO in 2018. Ms. Johnson earned a master’s degree in business administration from the F.W. Olin School of Business at Babson College and a bachelor’s degree from the University of Central Florida. “I was drawn to MetrumRG because of the mission of defeating disease, and I am committed to ensuring this continues to be our compass,” Ms. Johnson said. “We are a trusted partner to our scientific community and to our customers and I look forward to listening to and engaging with everyone who works with MetrumRG. I am grateful for the opportunity to empower my teammates to bring their expertise, insight, and innovation to all we do.” ABOUT METRUM RESEARCH GROUP Metrum Research Group, established in 2004, is a mission-driven company inspired by the goals of improving health and defeating disease. As a global leader in data analytic, modeling, and simulation solutions for the life sciences industry, MetrumRG derives insights and guides decision-making for customers by integrating knowledge and building a quantitative understanding of disease and therapeutic interventions. MetrumRG has delivered the highest quality solutions in quantitative science and technology to more than 200 companies while growing the science as thought leaders in the community. MetrumRG technology solutions include Metworx, a cloud-based computing platform, that empowers quantitative scientists to perform analyses and share results that support effective, data-driven decisions. Contact Details For Metrum Research Group media@metrumrg.com Company Website https://www.metrumrg.com/

October 13, 2022 10:05 AM Eastern Daylight Time

Image

It’s Time to Take the Lead: AmeriLife Introduces LeadStar Marketplace

AmeriLife

Today, AmeriLife Group, LLC (“AmeriLife”), in partnership with leading performance marketing and customer acquisition company Fluent, Inc. (“Fluent”) and insurtech leader Leadrilla, Inc. (“Leadrilla”), introduced LeadStar SM Marketplace, a proprietary, private leads platform created with and exclusively for its affiliated agents. With more lead options than any existing platform, and an intuitive, mobile-optimized design and feature set, agents can expect to go from qualified customer inquiries to closing on the same day. LeadStar Marketplace delivers exclusive, real-time leads as well as inbound and warm-transfer calls – directly to field agents – at the industry’s best prices. With the ability to customize lead volume and types against individual agents’ needs, LeadStar Marketplace empowers agents with unmatched flexibility, reliability and performance to accelerate their sales and grow their businesses. “When AmeriLife and its partners set out to build LeadStar Marketplace, we did so with one goal in mind: creating more opportunities for our agents,” said Scott R. Perry, chairman and CEO of AmeriLife. “Today’s announcement is about so much more than introducing a best-in-class leads platform – it’s about delivering more qualified prospects, a requirement for any agent in today’s highly competitive landscape. LeadStar Marketplace is that comprehensive, compliant and easy-to-use solution, and we’re excited to bring it to the market.” With LeadStar Marketplace, agents will benefit from: Sign-up to sales on the same day: With an intuitive, front-end design and mobile-optimized experience to take business anywhere, agents can expect to go from sign-up to selling within the same day, guaranteed. LeadStar Marketplace also has agents covered, providing technical support and sales tips with a dedicated support team and a rich library of on-demand training. Worry-free compliance: All lead sources in the LeadStar Marketplace are CMS, TCPA and consumer-protection compliance verified before they’re delivered to agents. As the system dynamically updates with regulatory changes, agents can be sure their leads will remain compliant. Combined with seamless and fully CMS-compliant inbound call recording and storage capabilities – at no additional cost – agents can focus on what they do best: serve their customers. Leads on agents’ schedules: LeadStar Marketplace is more than leads on demand – it’s leads when agents demand them. With flexible campaign management, agents can easily select dates, times and lead types to be delivered on their schedules, with the ability to pause and resume campaigns at the click of a button. And because LeadStar Marketplace provides exclusive, real-time data leads, agents won’t miss a beat as they connect with actively shopping customers. “Fluent leverages its best-in-class digital and call solutions to verify intent and match consumers with the health and life insurance products they’re in the market for today,” said Don Patrick, CEO of Fluent. “Through this partnership, we’ve created a marketplace that can easily elevate and streamline the sales process for agents and consumers alike, driving a quality solution for all.” “Leadrilla’s proprietary customer acquisition, routing and management software allows brands with distributed sales teams to gain full control and transparency into their sales performance,” said Koby Hastings, founder and CEO of Leadrilla. “The launch of LeadStar Marketplace is a game-changer for the industry, positions AmeriLife as a leader in insurance technology, and provides their agents with the tools they need to succeed.” “The demand for Medicare and life insurance solutions are growing rapidly, as are the questions many customers have about what coverage is right for them,” added William DeCourcy, senior vice president of Growth Marketing and Customer Acquisition for AmeriLife and product lead for LeadStar Marketplace. “LeadStar Marketplace was designed to seamlessly connect customers to our agents, quickly get their questions answered, and deliver the best coverage in near real-time to help them live longer, healthier lives.” For more information on LeadStar Marketplace and to request access, visit LeadStarHub.com/Marketplace. ### About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. About Fluent, Inc. Fluent, Inc. (NASDAQ: FLNT) is a global data-driven performance marketing company and trusted growth partner for leading brands. Experts in creating value for consumers, Fluent leverages its consumer database, digital media portfolio, and proprietary data science and technology to deliver outcome-based solutions for marketers. Founded in 2010, the company is headquartered in New York City. About Leadrilla, Inc. As an enterprise lead acquisition, routing and management platform for distributed sales teams across a variety of industries, Leadrilla provides the key to success for growth-oriented sales organizations. Leadrilla’s platform brings data-driven insights plainly into focus at each stage of the customer acquisition process, improving companywide performance at scale beginning with each individual agent. Founded in 2018, Leadrilla is a software company headquartered in Lexington, KY. For more information, visit Leadrilla.com or reach out to us at media@leadrilla.com. Contact Details AmeriLife Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Fluent, Inc. Media Relations marketing@fluentco.com Leadrilla, Inc. Media Relations media@leadrilla.com Company Website https://amerilife.com/

October 13, 2022 10:00 AM Eastern Daylight Time

Brüush CEO (NASDAQ: BRSH) Talks To Benzinga About Disrupting Oral Care

Bruush Oral Care Inc.

Click Here To Download The Latest Research Report on Brüush Benzinga had the pleasure of speaking with Brüush CEO and Founder, Aneil Manhas about the company’s history and where they are going. Here is what Manhas had to say: Benzinga - What was the inspiration for Brüush? Manhas was really interested in the success of two brands in particular - Harry’s and Dollar Shave Club. He had witnessed both of those companies take off in the early 2010s with a subscription-based model and oral care products seemed like an ideal fit for a similar model, but no one was doing it. Manhas saw a lot of similarities between the hassle of purchasing razor heads and replacement brush heads for an electric toothbrush. In both instances, the cost is expensive and the retail buying experience is annoying. He saw an opportunity to disrupt the electric toothbrush industry in the same way that Dollar Shave Club and Harry’s disrupted the razor market. Manhas shared, “If you’re going to the store to purchase an electric toothbrush or replacement brush heads, they are often locked up in cases within the aisle, which requires finding a store attendant to gain access and then figuring out what brush head is compatible with your device. It’s a miserable experience. I saw a problem and Brüush was my solution.” Benzinga - What sets your company apart from other brands offering electric toothbrushes? Currently, Brüush’s main competitors are the major brands like Oral B and Phillips. These brands are selling their high-end models for over $200, so the first thing that sets apart the Brüush toothbrush is the price point. Brüush is selling a top-of-the-line quality electric toothbrush that’s comparable to high-end models that retail for over $200 for a much cheaper price of $79. Manhas believes that the company has done an excellent job of creating a premium product for an affordable price. “When you get your Brüush toothbrush, you can immediately tell it is a premium product.” It’s what he likes to call “affordable luxury”. Manhas also highlighted how Brüush’s brush head refill subscription model is incredibly convenient for consumers. If someone likes their product, they can sign up for the subscription model, where they are shipped 3 brush heads every 6 months for $18 ($6/head). That level of convenience really appeals to consumers, especially post-pandemic, by helping them avoid needless store trips. The subscription model is something that Manhas believes is a strong draw, as he says that over 80% of customers opt-in for the brush head refill subscription. Manhas also believes Brüush has created an “experience” for consumers. He spent a lot of time focusing on the product's design, as he wanted to avoid creating a clunky and outdated toothbrush that looked like a medical device. He wanted to create a sleek unit that people would be proud to showcase in their bathroom. He paid a lot of attention to detail not only to the toothbrush itself, but also the packaging. The box is sleek, sexy and clean. When you open the Brüush packaging, it is a very Apple-esq experience that’s unlike any other electric toothbrush on the market and naturally becomes a very shareable moment on Instagram. Benzinga - Why do you think Millennials and Gen Zers gravitate to your brand? Manhas highlighted an estimated 70% of Brüush’s customers are within the 18-45 range, which is different from other electric toothbrush brands that skew to an older customer base. He shared that they are having wild success with millennials and Gen Zers, largely coming from their willingness to do what he called “disrupting oral care”. For the majority of their customers, the Brüush brand is their first electric toothbrush and Manhas noted that the company is very much going after that big market of manual brush users and trying to convince them there has never been a more opportune time to upgrade from manual to electric. Brüush has positioned itself as the go-to oral care brand for millennials and Gen Zers by shying away from traditional marketing initiatives such as television advertising and print media and instead directing their marketing efforts on digital channels where they have seen success. Brüush is also less focused on the type of statistics that oral care marketing has traditionally used like “9 in 10 dentists recommend” and opted for more personal messaging that resonates with their target audience. Manhas explains that the brand is trying to breathe life into oral care, which has typically been a very dull and boring category. “I want people to look forward to brushing their teeth. We want to deliver customers more than just a great product…we want to have a brand that speaks to them and one they can relate to on a personal level.” Brüush was super excited to partner with comedian Kevin Hart, a partnership that evolved organically. "I loved Brüush from the first time I tried it. Our partnership makes a lot of sense given we both are obsessed with smiles, everything about it feels natural and authentic.” said Hart in a statement. Manhas added that he believes the partnership has helped position the brand in a unique way but notes that Kevin Hart is just one piece of Brüush’s marketing puzzle. Brüush is active on social media and works with micro-influencers who showcase their real-life experience with the product. This, again, comes back to creating an experience for potential customers that is both authentic and enjoyable. Benzinga - What is on the horizon for Brüush? Manhas shared that Brüush has a lot in store over the next few months. Being the perfect gift, the holiday season is a peak period for sales. The company will also be releasing some holiday limited edition colors, so stay tuned for that announcement. Brüush is also expanding its oral care product line in early 2023, with the launch of toothpaste, mouthwash, dental floss, and a whitening pen in the first quarter, and an electric toothbrush designed for kids in the second quarter. Manhas shares that all the new products will have the same premium look and feel as the Brüush toothbrush. Manhas says that his ultimate goal for Brüush is to “own the bathroom” and create a diverse product line that appeals to millennial and Gen Z customers. He is optimistic about his goal, sharing that currently Brüush has a 90% 5-star rating on its website, a very low churn rate on the brush head refill subscription, and a product return rate of only 1%, which is pretty much unheard of for an e-commerce CPG company. He says, “We have a value proposition that is really resonating with the consumer. Our biggest challenge is awareness, so we just need to continue to work on getting the word out.” About Bruush Oral Care Inc. Bruush Oral Care Inc. is on a mission to inspire confidence through brighter smiles and better oral health. Founded in 2018, Brüush is an oral care company that is disrupting the space by reducing the barriers between consumers and access to premium oral care products. The Company is an e-commerce business with a product portfolio that currently consists of a sonic-powered electric toothbrush kit and brush head refills. Brüush has developed a product to make upgrading to an electric brush appealing with three core priorities in mind: (i) a high-quality electric toothbrush at a more affordable price than a comparable electric toothbrush from the competition; (ii) a sleek, countertop-friendly design; and (iii) a convenient brush head refill subscription program that eliminates the frustrating experience of purchasing replacement brush heads at the grocery/drug store. The Company is rooted in building a brand that creates relevant experiences and content, with the goal of becoming the go-to oral care brand for millennials and Generation Z.For more information on Bruush Oral Care Inc visit https://bruush.com. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR - Colette Eymontt colette@tradigitalir.com Company Website http://www.tradigitalir.com

October 13, 2022 09:14 AM Eastern Daylight Time

mTuitive and PathPresenter Partner to Bring Structured Pathology Reporting and Compliance to Digital Pathology Workflow

PathPresenter

mTuitive, Inc. and PathPresenter Corporation today announced a new partnership to deliver an enhanced pathologist reporting experience that will unify powerful digital tools, AI algorithms, and synoptic reporting to produce precise, comprehensive, data-driven reports that enable precision patient care and unparalleled retrospective analysis. Together, the two organizations bring their medical and technical expertise to laboratories and hospitals ensuring compliance with national requirements while fueling important analytic and reporting work downstream. mTuitive’s flagship product, CAP eFRM™, integrates with PathPresenter image management system using the latest SMART-on-FHIR technology for a seamless interface that boosts efficient workflows for their users. The partnership fuels the tight integration between PathPresenter and mTuitive, allowing PathPresenter to prepopulate fields in CAP eFRM, pulled directly from PathPresenter’s digital viewer. This boosts physician efficiency without any detriment to the quality or completeness of their work — in fact, required fields and other operations improve and ensure comprehensiveness of these reports, which can be signed out directly in PathPresenter, xPert, or the laboratory’s information system. “As digital adoption in pathology grows, healthcare providers will need to develop clear strategies for effectively managing the workload that faces the dwindling pathologist population,” commented Imogen Fitt, Market Analyst at Signify Research. “Automating and standardizing the reporting process will increase efficiency by enabling pathologists to focus on more complex tasks. Ultimately this will be essential in providing the short-term ROI providers seek.” A customized pre-analytic workflow starts in the PathPresenter image management system by prioritizing cases to be reviewed. Contextually understood data is extracted using AI algorithms run on the images and prepopulates critical diagnostic values into reporting protocols in CAP eFRM. CAP eFRM allows the pathologist to complete their diagnosis and build a comprehensive synoptic report that can be signed out or returned to the APLIS. In the analytical phase, real-time results are exchanged between PathPresenter’s powerful real-time tools, third-party plug-ins, and CAP eFRM. Discrete, coded data is retained with the annotated images for future use. The structured data in CAP eFRM and PathPresenter can be searched and utilized for reporting and analytics, sharing downstream with data lakes and registries, and variety of services like identifying images to train machine learning models, validating AI results, or identifying appropriate tissue for research projects. “Automating reporting workflow will be a boon to digital pathology adoption in institutions,” added Patrick Myles, CEO of PathPresenter. “Partnering with reporting workflow leader, mTuitive, is an important step forward to help deliver on the promise of increased efficiency in digital workflows.” “This partnership will unleash the power of the data that pathologists collect while also continuing to make for more accurate and more efficient reporting,” said Colin Murphy, CEO of mTuitive, Inc. mTuitive and PathPresenter maintain standards put forth by organizations like College of American Pathologists (CAP) promoting best practices for reporting and compliance with accreditation requirements. The information captured through the digital viewer and within the reports can also be SNOMED-CT coded to assist in better communication between physicians and even faster workflow within the laboratory’s system. About PathPresenter PathPresenter is the image sharing platform for pathology, on a mission to democratize access to the world’s pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical platform to access and use best-in-class AI models. Founded in 2017 by dermatopathologist and digital pathology pioneer, Dr. Rajendra Singh, PathPresenter has been adopted by 25+ tier one medical institutions for clinical care, education, and research, and has built a thriving community of 45,000+ users in 172 countries to easily view and share digital pathology images and knowledge. For more information visit www.pathpresenter.com. About mTuitive, Inc. Based out of Massachusetts, mTuitive was the first company to license the Cancer Protocols content from the CAP for pathology and the ACS for surgery.Â mTuitive has been leading the way with synoptic reporting in healthcare since 2003. Co-founded by a surgical pathologist who saw how much powerful information is locked inside unsearchable, unstructured text. The company developed new technology and proprietary authoring tools to create reports that would be easy-to-use for physicians, vastly improving the workflow while ensuring comprehensiveness of the reports and gained much success worldwide through its innovative approaches. Eventually partnering with the College on the CAP eFRM pathology reporting solution, mTuitive has also created similar reporting offerings for surgery, mental health, radiology, and more. Find more information at www.mtuitive.com or by calling 508.771.5800. Contact Details PathPresenter Cory Batenchuk, SVP of Operations +1 873-355-9913 cory@pathpresenter.com mTuitive, Inc. Rob Dean – Director of Marketing +1 508-280-8452 Rob.Dean@mtuitive.com Company Website https://pathpresenter.net

October 12, 2022 03:23 PM Eastern Daylight Time

Syntekabio and MDBioLab Collaborate on Groundbreaking Anticancer Research (226330:KOSDAQ)

Syntekabio, Inc.

Syntekabio (226330:KOSDAQ)(226330:KS), an AI drug discovery and development company, announced a joint research partnership with MDBioLab, an innovative new anticancer drug development company based in South Korea. Syntekabio’s AI platform DeepMatcher® is used to predict compound-target protein binding to identify the mechanism of action for MD102, an oral delivery drug candidate for the indications for renal cell carcinoma and triple-negative breast cancer developed by MDBioLab. DeepMatcher® is also expected to support the expansion of MD102 for alternative diseases. MD102 is the first-in-class small molecule drug candidate for an inhibitor of Transglutaminase 2 (TG2) that is a cancer-specific target to participate in both facilitating and inhibiting apoptosis, playing both anti- and pro-apoptotic roles. Its anticancer efficacy through TG2 inhibition was successfully confirmed via in vivo xenograft tumor-model test. It is currently under development as a small molecule therapeutics for kidney cancer. TG2—the target protein of MD102—changes drastically its protein structure depending on the environment in and outside of the cell. Hence, its protein function and related diseases also vary accordingly. Both companies are confident that using DeepMatcher® to predict the interaction mechanism of MD102 and TG2 will provide a critical insight to understand the mechanism of action in details; therefore, it effectively supports future drug development strategies. DeepMatcher® is ideal for mechanism of action (MOA) research, as it examines indication expansion of existing candidates that have already been derived, and accurately screens and optimizes new candidates as well. Hyun-chul Jung, head of R&D at MDBioLab, said, “We welcome this joint research opportunity with Syntekabio. As a global leader in AI-based drug discovery and development platforms, Syntekabio is a powerful partner to strengthen our R&D competitiveness. DeepMatcher® technology will play a crucial role in the acceleration of innovative new anti-cancer drug development projects.” “MDBioLab is a formidable industry innovator in development of first-in-class therapeutics for anti-cancer target proteins,” said Syntekabio CEO Jong-sun Jung. “Our commitment to developing innovative new drugs is deeply rooted in the synergy based on Syntekabio’s advanced AI technology and MDBioLab’s R&D capabilities. Starting with MD102, we look forward to broadening and deepening our collaborations in the future.” For business development meetings and information about Syntekabio’s products and services, contact the New York office at +1 (212) 371-2544 or admin@syntekabiousa.com. SyntekaBio is a global artificial intelligence (AI) and big data-based drug discovery and development company, headquartered in South Korea since 2009, with its U.S. operations bringing innovative technologies and science to create transformative medicines worldwide that are compliant with international standards to cure diseases and improve people's lives. Find out more about DeepMatcher®, NEO-ARS™, NGS-ARS™ and PGM-ARS™ at www.syntekabiousa.com. Contact Details Syntekabio USA | WMSG Sabina Lee +1 201-408-5342 wgroup@wmedical.org

October 12, 2022 12:11 PM Eastern Daylight Time

MedAcuity Appoints New VP of People Operations and Director of Quality Assurance

MedAcuity

MedAcuity, the go-to Boston-based software development partner for leading MedTech companies, today announced the appointments of Jeanne Raney as vice president of people operations and Andy Sageman as director of quality assurance. MedAcuity, which marks its 15 th anniversary this year, prioritizes team development and a quality-first mindset as integral to the success of the strategic consulting and software development work done in partnership with its MedTech and robotics clients. As MedAcuity’s vice president of people operations, Jeanne will prioritize humanizing business processes and continuously improving employee training, development, engagement and retention. Jeanne comes to MedAcuity with over 25 years of human resource management / people operations experience in industries including professional and managed services/consulting, clinical research, and managed IT services. She brings expertise in talent management, policy development, coaching, management training, benefits, and employee communications. Jeanne has her BBA in general business and finance from UMASS Amherst, her MBA from Suffolk University, and has both her SHRM-SCP and SPHR certifications. “Putting people first has always been a cornerstone of our company values and continuing to do so is critical to the success of our business,” said Karl Pessinis, COO, MedAcuity. “Jeanne will be instrumental in evolving the MedAcuity culture to create an even more positive and inspiring environment where team members know they are valued and have access to needed resources for professional development. We want everyone who works at MedAcuity to feel supported and to be proud of the work we are doing here, and Jeanne has the ideal expertise to lead our people-centric initiatives.” As director of quality assurance, Andy will ensure that MedAcuity’s engineering teams bring a quality mindset to each client project to ensure the highest standards are achieved in the delivery of its services and capabilities. Andy comes to MedAcuity with over 25 years of quality leadership and quality engineering experience in the medical device industry. During his career, Andy has provided quality engineering, quality leadership and project management support for the development and commercialization of continuous glucose monitors and insulin infusions pumps for Diabetes patients (Becton, Dickinson and Company), Laser Vision Correction systems for Lasik surgery (Abbott Medical Optics), and cardiac output monitoring systems, mechanical/porcine heart valves and pressure monitoring devices for cardiac patients (Medtronic-Heart Valve Division). Andy holds a BS in electrical engineering from Michigan State University. “With our sights set on the next 15 years of successfully partnering with clients to accelerate the development of complex software solutions for all classes of medical devices and robotics solutions, Andy will be a great asset to our team,” said Dennis Fuccione, president & co-founder of MedAcuity. “He is motivated by bringing innovative products to the market that improve people’s health and well-being, and will focus on developing common sense QA practices and expanding our QA service offerings for our MedTech software development projects.” About MedAcuity MedAcuity is a specialized engineering firm that focuses on medical technology software development. The trusted and experienced firm was founded in 2007 by a team of seasoned software engineers who identified opportunities to fill gaps in the engineering expertise and efficiency facing the medical technology industry. MedAcuity offers extensive experience across the MedTech industry with full life-cycle software development and subspecialties in other areas including tool validation, algorithm development, and cybersecurity. www.medacuitysoftware.com Contact Details SVM PR Jordan Bouclin +1 401-490-9700 jordan.bouclin@svmpr.com Company Website https://www.medacuitysoftware.com/

October 12, 2022 10:15 AM Eastern Daylight Time

Fullintel Appoints James Rubec as Head of Product

Fullintel, LLC

Fullintel, a leading media monitoring and analysis services company specializing in human curation combined with powerful predictive intelligence, is pleased to announce it has appointed James Rubec its new Head of Product. A former senior director of product management and director of content and licensing management at Cision and Cision Canada, Rubec is an industry leader with a history of thought leadership and innovative data storytelling around how media influences the world around us. Rubec has used data to predict elections, uncover societal trends, and improve internal business processes. His work has appeared in outlets such as The Financial Post, Yahoo Finance, Variety Magazine, and the CBC. Helping communicators understand the media landscape and capitalize on opportunities Rubec has now joined Fullintel to collaborate with clients to identify opportunities and use cases for PredictiveAI™, Fullintel’s human-in-the-loop machine learning solution designed to predict the virality of media stories and social posts. “My goal is to help PR professionals tell more effective stories and help organizations take advantage of the predictive tooling that Fullintel has developed,” says Rubec. “By better understanding the landscape through PredictiveAI™, communicators can identify an issue before it becomes a crisis or better identify stories that should be amplified to make them powerful promotional tools. We’re taking PR past gut instinct and into data science.” He’ll be focused on expanding the product roadmap for PredictiveAI™, to make it an even more agile and flexible tool as part of the Fullintel Hub, Fullintel’s real-time media monitoring platform. A history of using data to improve products and processes Rubec got his start as a reporter in Ottawa, Ontario and Yellowknife, Northwest Territories, working as a PR professional in Toronto before transitioning to the media intelligence space nearly a decade ago. Since then he’s primarily focused on building tools and processes to help organizations move faster, engage the media more efficiently, and better understand their industries. “James has shown he’s a leader who can motivate action through data,” said Fullintel President Andrew Koeck. “He’ll work closely with our clients to evolve our software offerings and build a product roadmap to leverage our real-time monitoring and analysis tools, to provide insights and data never before available from any vendor.” Rubec’s addition builds on Fullintel’s growing momentum in the PR measurement industry, culminating in the company winning Gold, Silver, and Bronze awards at the 2021 AMEC Awards for media measurement. His hiring follows Fullintel’s hiring of Angela Dwyer as Head of Insights, and the company’s shortlisting for five 2022 AMEC Awards for outstanding media measurement. Fullintel combines best-in-class technology with expert content curation to deliver the most relevant, cost optimized media monitoring, daily news briefs, and media analysis possible. Our analysts curate print, online, social media, broadcast, and influencer opinions in real time – compiled by technology, supplemented and verified by humans. Where technology alone fails, your dedicated analyst has you covered. Fullintel has offices in Cambridge, Mass., Ottawa, Ont., and Nagercoil, India. Contact Details Samuel Chen +1 339-970-8005 schen@fullintel.com Company Website https://fullintel.com/

October 12, 2022 10:11 AM Eastern Daylight Time

Image

AIHM Annual Conference Features More than 50 International Leaders in Integrative Health and Medicine

Academy of Integrative Health and Medicine

The Academy of Integrative Health and Medicine (AIHM) is hosting its 2022 conference October 28 to 30, 2022, at the Paradise Point Resort & Spa in San Diego. For the first time, the hybrid conference will occur in-person and virtually and includes dozens of speakers such as Dr. Deepak Chopra, Dr. Mimi Guarneri, Dr. Shamini Jain, Dr. Scott Shannon, Dr. Sara Gottfried, Dr. Romie Mushtaq, and many more. During the event, hundreds of healthcare workers presenting a vast array of industries and professions will learn about the latest in evidence-based integrative health and medicine through various presentations, panels and networking events. Attendees are also able to earn CME credits for attending both in-person and online. "After taking the conference virtual during COVID, we decided to create a hybrid model and expand how people can attend and participate at our 2022 conference," said Tabatha Parker, Executive Director, AIHM. "Both in-person and virtual tracks provide a rich and engaging educational experience that cultivates community and networking opportunities," she added. This year's program includes thought-provoking discussions on topics in the news such as diversity, equity and inclusion in health education, anti-racism in medicine, climate change and healthcare, and utilizing psychedelics in integrative health. AIHM also designed a unique conference experience to nourish the mind and body with unique self-care activities, healthy food and a regenerative location in nature for attendees. For more information, including a full list of speakers and topics, please go to www.aihm.org/conference. Please note that in-person registration is limited and filling quickly. About AIHM Founded in 1978, the Academy of Integrative Health and Medicine (AIHM) is the leading interprofessional organization for traditional, complementary, and integrative health practitioners worldwide. In 2021, AIHM merged with the Academic Collaborative of Integrative Health (ACIH). Together, they are working to advance integrative health on a global scale and transform healthcare through education, leadership, collaboration, research, and advocacy. Founded in 1978, the Academy of Integrative Health and Medicine (AIHM) is the leading interprofessional organization for traditional, complementary and integrative health practitioners worldwide. In 2001, AIHM merged with the Academic Collaborative of Integrative Health (ACIH). Together, they are working to advance integrative health on a global scale and transform health and wellness through education, leadership, collaboration, research and advocacy. For more information, visit aihm.org or follow @aihmglobal on Facebook, Instagram, and Twitter. Contact Details AIHM Caitlin Marinaro +1 858-240-9033 cmarinaro@aihm.org Company Website https://aihm.org

October 12, 2022 09:06 AM Eastern Daylight Time

Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells

Unicycive Therapeautics, Inc.

You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick? In addition to powering healthy cells, mitochondria are also important players in certain diseases. This is especially true in kidney disease. While kidney cells make up only 1% of our body weight, they consume over 10% of our daily energy supply. When either acute or chronic disease strikes these vital organs, the health of the mitochondria can literally be the difference between life and death. Specialized pores inside the mitochondria called mitochondrial permeability transition (MPT) pores regulate programmed cell death—or apoptosis. Under disease conditions, MPT pores are stuck open allowing fluid to rush in causing swelling which leads to the death of the cell. What if you could close these pores? Would that restore the normal function of damaged mitochondria and possibly be a cure for disease? That’s just what a California-based biotechnology company specializing in diseases of the kidney is hoping to do. Unicycive Therapeutics Inc. (NASDAQ: UNCY) recently announced findings from a preclinical trial for their drug called UNI-494 that reduced a known biomarker of ischemic injury that is present in acute kidney injury (AKI), a result described as “very encouraging” by a leading expert in the field of AKI research. UNI-494 is a potent activator of the mitochondrial adenosine triphosphate-sensitive (ATP) potassium channel (mitoKATP). That’s important because when these channels are activated, they close the MPT pores and prevent the damage that leads to cell death. Mitochondrial dysfunction is closely associated with kidney issues, including (AKI). Affecting over 13 million people worldwide each year, AKI increases the risk of mortality by 23.9% in adults and 13.8% in children. Companies like DaVita Inc. (NYSE: DVA) and Akebia Therapeutics Inc. (NASDAQ: AKBA) are among the companies seeking solutions to a variety of renal diseases. Unbelievably, however, there are still no Food and Drug Administration (FDA)-approved drugs for AKI. Sadly, damage to mitochondria is seen in other diseases as well, including cardiovascular, liver and eye degeneration. While Unicycive is initially focused on producing a treatment for AKI and chronic kidney disease (CKD), it believes that the mechanism of action of UNI-494 may also be applicable for the treatment of other diseases where the mitochondria are affected. The company is now beginning its next milestone, filing to begin Phase 1 human trials of the drug. “We are excited to report this key finding,” Unicycive CEO Dr. Shalabh Gupta said. “We remain on track to file a regulatory submission by the end of 2022 that will allow us to initiate our Phase 1 study with UNI-494.” If the FDA approves the drug, it would be the first drug for AKI available on the market. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Anne Marie Fields - Stern Investor Relations +1 212-362-1200 annemarie.fields@sternir.com Company Website https://unicycive.com/

October 12, 2022 08:00 AM Eastern Daylight Time

1 ... 200 201 202 203 204 ... 307